Branded Wegovy and Zepbound for a small telehealth brand

Operators searching for NovoCare pharmacy telehealth partners, or the LillyDirect equivalent, are usually asking a business question in a regulatory costume. With the manufacturers selling branded Wegovy and Zepbound directly to cash-pay patients, what is left for a small telehealth brand to earn? The answer is the clinical service. Manufacturer direct pricing collapsed the medication margin that compounded programs ran on. That makes the consult and the program fee the business, and it makes a 0% markup arrangement the only platform model that still adds up.

What NovoCare and LillyDirect are

NovoCare Pharmacy is Novo Nordisk's direct-to-patient channel for cash-pay Wegovy. CNBC reported in March 2025 that the company began offering Wegovy through it at $499 a month for self-pay patients, shipped to the home. LillyDirect is Eli Lilly's equivalent for Zepbound, selling single-dose vials at cash prices through a mail-order pharmacy. Both exist for the same reason: a large share of the patients who want these drugs have no coverage for them, and the manufacturers would rather sell to those patients at a lower cash price than lose them to compounded products.

The design feature that matters is that neither channel replaces the prescriber. A patient still needs a valid prescription from a licensed clinician. The manufacturer's pharmacy dispenses; it does not diagnose, prescribe, adjust a dose or answer a message about nausea at nine on a Tuesday night. That leaves the clinical encounter, and the ongoing management around it, as the piece a telehealth brand supplies.

How routing works, and who the manufacturers partner with

In the simplest arrangement, the brand's affiliated provider writes the prescription and the patient buys through the manufacturer's channel at the manufacturer's price. The brand never touches the medication. The manufacturers have also struck direct arrangements with larger telehealth companies. Fierce Healthcare reported that Lilly partnered with Ro, LifeMD and Teladoc to offer low-cost Zepbound, and BioPharma Dive reported a 2026 agreement between Hims & Hers and Novo Nordisk covering Wegovy and Ozempic. Those are press accounts of deals whose terms are private. A small brand should not assume the same terms are on offer to it, and it does not need them.

What a small brand can do is route. Its provider prescribes; its storefront or patient portal sends the patient to the manufacturer's channel, or the brand's pharmacy partner dispenses the branded product at wholesale plus a dispensing fee. Either way the medication price is set by someone other than the brand. The brand's pricing power over medication is gone, and the sooner the model reflects that, the less money gets lost learning it.

What oral semaglutide pricing changed

The injectable cash prices already made compounded programs hard to defend on value. Oral semaglutide moved the line again. FDA approved an oral form of Wegovy on December 22, 2025, according to press coverage of the approval, and press reports at launch put the cash price through telehealth channels at roughly $149 a month. The current figure belongs to the manufacturer and it moves, so check the manufacturer's page before quoting it to anyone.

A pill with no cold chain, no needle, and a cash price in that range removes most of the reasons a patient tolerated a compounded injection. It also removes the argument a brand once made to itself: that compounding was the only way to reach a price a cash patient could afford. When the branded, FDA-approved product is the cheapest option in the market, the brand cannot be in the business of selling a cheaper drug. It has to be in the business of a better program.

When the branded, FDA-approved product is the cheapest option in the market, the brand cannot be in the business of selling a cheaper drug.

Margin before and after: compounded versus branded

Consider how a compounded GLP-1 program made money in 2024. The brand bought compounded semaglutide from a 503A pharmacy or a 503B facility at a wholesale price that was a small fraction of the branded list price, bundled it into a monthly subscription, and kept the difference. The medication line was the margin. The consult was a cost of doing business, sometimes given away. Platforms priced accordingly, with a markup on each fill and often a revenue share on top, and the brand tolerated both because the spread was wide enough to hide them.

Now run the same brand on branded product. The patient pays the manufacturer's cash price, which CNBC reported at $499 a month for injectable Wegovy through NovoCare, or the oral price reported above. The brand does not set that number and cannot mark it up; a markup on top of a price the patient can see on the manufacturer's own website is a conversion problem before it is a compliance problem. The medication line contributes nothing. Whatever the brand charges on top is, by definition, the price of the clinical service.

Here is the arithmetic in words, without invented figures. Under a 0% markup arrangement with a flat per-consult fee, the brand's variable cost per patient is the consult fee for each visit plus payment processing, and the rest of the program fee is contribution margin. Under a markup-plus-revenue-share arrangement, the platform takes a percentage of that same program fee, and would also take a markup on any medication the brand's pharmacy dispensed, which for branded product means either the brand eats it or the patient walks. A percentage take on a business whose only margin is the service fee is a partner in the business, whatever the contract calls it. The zero pharmacy markup guide works through the numbers.

There is a second cost to the old model that shows up only after the switch. A platform that earned a spread on compounded fills had a reason to keep patients on the compounded product. A brand that earns on the program fee has a reason to keep patients on the program, on whichever product the prescriber chooses. Those are different businesses, and only one of them is still available.

Program-fee models that survive

Among small brands that have made the shift, the surviving models fall into a few shapes. They are not mutually exclusive, and most brands run at least two.

• A flat monthly program fee covering prescribing, follow-ups, dose adjustments and messaging, with the medication purchased by the patient at the manufacturer's price. This is the simplest to explain and the easiest to defend to a regulator, because the fee is plainly for clinical service.
• A per-visit fee with an optional membership. Patients who want a prescription and a periodic check-in pay per encounter; patients who want coaching, weekly weigh-ins and faster responses pay a membership. The entry price stays low while engaged patients get a reason to stay.
• A bundled program where the brand's pharmacy partner dispenses the branded product at wholesale plus a disclosed dispensing fee, with the program fee as a separate line. The medication is still passed through; the brand simply keeps fulfillment inside its own storefront and its own record.

In every case the fee has to buy something the patient can feel. Titration that is managed rather than merely scheduled. Side-effect questions answered the same day. A plan for what happens at goal weight, so the patient does not conclude that the program ended when the prescription did.

Program fees are also where discontinuation shows up on the P&L. The published research is sobering. A JAMA Network Open analysis available through PubMed Central found that 64.8% of patients without type 2 diabetes had discontinued GLP-1 therapy at one year, and a Blue Health Intelligence issue brief reported that 58% of patients stopped before reaching a clinically meaningful benefit. A brand that earns on the program fee rather than the fill has every reason to fight that curve. A platform that earns a markup has less.

What to ask a platform partner about branded fulfillment

The questions below separate a partner built for branded product from one still pricing as if the compounded spread existed.

• Whether the pharmacy network can dispense branded Wegovy, Zepbound and oral semaglutide at wholesale, and what the dispensing fee is, in writing.
• Whether the platform takes any markup on medication, and whether that includes branded product. A 0% figure belongs in the contract, not the pitch deck.
• Whether the platform takes a revenue share on program fees. If the program fee is the whole business, a share of it is a share of the business.
• How routing to a manufacturer channel works inside the patient portal: whether the patient leaves the brand's experience, and whether the brand keeps the record and the follow-up.
• What the per-consult fee is and what counts as a consult. Follow-ups and asynchronous check-ins drive program economics; their pricing matters more than the initial visit.
• Whether providers are licensed in every state the brand markets in, so a branded prescription can be written wherever a patient turns up.
• What the brand owns if it leaves: the patients, the records and the storefront, or a data export and a farewell email.

Tessic Health's published terms are one answer to that list: $25 flat per completed consult, 0% medication markup on every fill including branded product, no revenue share on any plan, month to month after a one-time setup fee, with plans from $1,000 a month. The weight-loss launch page describes the clinic setup, and why zero markup matters shows what the alternative costs at scale. The structure exists because the medication margin is gone, and a platform should not be pricing as if it were not.

Questions operators ask

Can a small brand become a NovoCare or LillyDirect partner? The partnerships reported in the press involve large telehealth companies, and neither manufacturer has published a program for small brands. A small brand does not need one. Its provider can prescribe the branded product, and the patient can buy through the manufacturer's channel or the brand's pharmacy partner without any agreement with the manufacturer.

Can a brand charge a markup on branded product dispensed through its own pharmacy partner? Legally that depends on state pharmacy law and on who is doing the dispensing. Commercially it fails, because the patient can see the manufacturer's price. A disclosed dispensing fee for the convenience of one storefront is defensible; a hidden spread is a refund request waiting to happen.

Does compounded product still have a place? As a documented, patient-specific exception, yes. As the default that carries the margin, no. The legal position is covered in a separate post on compounded semaglutide and tirzepatide in 2026.

What is a fair program fee? There is no published benchmark worth citing, and any figure a vendor quotes is a sales number. Price it from the cost side: provider time per patient per month, platform fees, acquisition cost spread over expected retention, and the margin the brand needs to keep the lights on. Then watch whether patients stay, because that is the only test that counts.

Will the oral product make injectables irrelevant to a telehealth brand? Not soon; the two serve different patients and the prescriber decides. What the oral product does is make the price argument for compounding impossible to win, and that is the change that matters for the model.

The medication was never really the product. Direct pricing just made that impossible to ignore. A brand that accepts it early builds a program worth paying for; a brand that fights it spends a year defending a margin that no longer exists.